← Back to Screener
United Therapeutics Corp (UTHR)
Price$544.62
Value ScoreC
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)1.36%
Price vs S&P 500 (4W)-7.35%
VGM Score55.68
Market Capitalization$23.64B
P/E Ratio (Annual)17.71x
All Metrics
P/CF (Annual)15.14x
Book Value / Share (Quarterly)$139.98
P/TBV (Annual)2.99x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)18.02%
Cash Flow / Share (Quarterly)$23.99
Price vs S&P 500 (YTD)3.34%
Gross Margin (TTM)86.58%
Net Profit Margin (TTM)40.61%
EPS (TTM)$27.09
10-Day Avg Trading Volume0.47M
EPS Excl Extra (TTM)$27.09
Revenue Growth (5Y)16.50%
EPS (Annual)$27.86
ROI (Annual)18.81%
Gross Margin (Annual)87.92%
Net Profit Margin (5Y Avg)38.31%
Cash / Share (Quarterly)$51.09
P/E Basic Excl Extra (TTM)18.36x
Revenue Growth QoQ (YoY)-1.62%
EPS Growth (5Y)19.27%
P/E Normalized (Annual)17.71x
ROA (Last FY)16.94%
Revenue Growth TTM (YoY)5.87%
EBITD / Share (TTM)$32.07
ROE (5Y Avg)16.20%
Operating Margin (TTM)45.29%
Cash Flow / Share (Annual)$23.72
P/B Ratio4.01x
P/B Ratio (Quarterly)4.40x
Net Income / Employee (Annual)$953,400
EV / Revenue (TTM)7.05x
Net Interest Coverage (TTM)42.15x
ROA (TTM)17.25%
EPS Growth QoQ (YoY)-12.15%
EV / EBITDA (TTM)14.67x
EPS Incl Extra (Annual)$27.86
Current Ratio (Annual)6.60x
Quick Ratio (Quarterly)4.50x
3-Month Avg Trading Volume0.49M
52-Week Price Return73.81%
EV / Free Cash Flow (Annual)21.60x
P/E Incl Extra (TTM)18.36x
Revenue / Employee (TTM)$2,264,100
Tangible BV / Share (Quarterly)$137.24
P/S Ratio (Annual)7.43x
Asset Turnover (Annual)0.40x
52-Week High$609.35
Operating Margin (5Y Avg)45.80%
EPS Excl Extra (Annual)$27.86
CapEx CAGR (5Y)54.73%
Tangible BV CAGR (5Y)16.52%
26-Week Price Return17.29%
Quick Ratio (Annual)6.28x
13-Week Price Return10.57%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.79x
Enterprise Value$22.36B
Revenue / Share Growth (5Y)14.85%
Asset Turnover (TTM)0.42x
Book Value / Share Growth (5Y)16.34%
Revenue / Employee (Annual)$2,273,400
Inventory Turnover (Annual)2.25x
Pretax Margin (Annual)53.85%
Cash / Share (Annual)$66.91
3-Month Return Std Dev42.25%
Gross Margin (5Y Avg)90.20%
Net Income / Employee (TTM)$919,600
EBITDA CAGR (5Y)20.05%
EBITDA Interim CAGR (5Y)18.91%
ROE (Last FY)18.81%
Net Interest Coverage (Annual)14.96x
EPS Basic Excl Extra (Annual)$27.86
P/FCF (TTM)23.37x
Receivables Turnover (TTM)10.00x
EV / Free Cash Flow (TTM)22.10x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$27.09
Receivables Turnover (Annual)10.11x
ROI (TTM)19.24%
P/S Ratio (TTM)7.46x
Pretax Margin (5Y Avg)49.28%
Revenue / Share (Annual)$66.44
Tangible BV / Share (Annual)$160.67
Forward P/E18.96x
Free OCF CAGR (5Y)8.25%
Price vs S&P 500 (52W)45.60%
P/E Ratio (TTM)18.36x
EPS Growth TTM (YoY)8.02%
Year-to-Date Return14.28%
5-Day Price Return-2.04%
EPS Normalized (Annual)$27.86
ROA (5Y Avg)13.63%
Net Profit Margin (Annual)41.94%
Month-to-Date Return-2.54%
Cash Flow / Share (TTM)$19.22
EBITD / Share (Annual)$32.95
EPS Growth (3Y)22.94%
Operating Margin (Annual)46.89%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)15.12x
ROI (5Y Avg)14.85%
P/E Excl Extra (TTM)18.36x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$27.09
P/TBV (Quarterly)4.49x
P/B Ratio (Annual)2.96x
Inventory Turnover (TTM)2.47x
Pretax Margin (TTM)50.75%
Book Value / Share (Annual)$162.60
Price vs S&P 500 (13W)0.82%
Net Margin Growth (5Y)3.86%
Beta0.58x
P/FCF (Annual)22.83x
Revenue / Share (TTM)$67.16
ROE (TTM)19.24%
52-Week Low$272.12
vGradeC
gGradeC
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 265.82est. 7.01
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.05
4.10
4.10
4.09
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
UTHRUnited Therapeutics Corp | C | C | B | $544.62 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
United Therapeutics Corp develops and markets therapies for pulmonary arterial hypertension (PAH), a rare and progressive lung disease characterized by elevated blood pressure in the pulmonary arteries. The company's portfolio centers on treprostinil-based treatments, with Tyvaso DPI (inhalation powder) as its primary revenue driver, supported by Remodulin (injection), Orenitram (extended-release tablets), Adcirca (tadalafil), and Unituxin. The U.S. market generates the majority of revenue, though the company maintains a presence in international markets.